STOCK TITAN

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced its participation in the Society for Cardiac Robotic Navigation's Annual Meeting on October 28-29 in Lisbon, Portugal. The conference will feature over forty physicians from across the globe, showcasing Stereotaxis' robotic technologies in presentations, panels, and demonstrations.

Key topics include:

  • Artificial intelligence and robotic automation in cardiology
  • Clinical experience with the MAGiC ablation catheter and Abbott's EnSite X mapping system
  • Robotic catheter innovations for high-density mapping and pulsed field ablation
  • Advancements in Genesis and GenesisX robotic systems
  • Alternative access techniques from the arm
  • Best practices for robotics in complex arrhythmia treatment

David Fischel, Stereotaxis Chairman and CEO, expressed excitement about the conference, noting the growing importance of robotics in advancing cardiology.

Stereotaxis (NYSE: STXS), leader nella robotica chirurgica per interventi endovascolari minimamente invasivi, ha annunciato la sua partecipazione al Meeting Annuale della Society for Cardiac Robotic Navigation che si terrà il 28-29 ottobre a Lisbona, Portogallo. La conferenza presenterà oltre quaranta medici da tutto il mondo, mostrando le tecnologie robotiche di Stereotaxis attraverso presentazioni, pannelli e dimostrazioni.

I temi principali includono:

  • Intelligenza artificiale e automazione robotica in cardiologia
  • Esperienze cliniche con il catetere di ablazione MAGiC e il sistema di mappatura EnSite X di Abbott
  • Innovazioni nei cateteri robotici per mappatura ad alta densità e ablazione a campo pulsato
  • Progressi nei sistemi robotici Genesis e GenesisX
  • Tecniche di accesso alternative dal braccio
  • Best practices per la robotica nel trattamento delle aritmie complesse

David Fischel, Presidente e CEO di Stereotaxis, ha espresso entusiasmo per la conferenza, sottolineando l'importanza crescente della robotica nel progresso della cardiologia.

Stereotaxis (NYSE: STXS), líder en robótica quirúrgica para intervenciones endovasculares mínimamente invasivas, anunció su participación en el Meeting Anual de la Society for Cardiac Robotic Navigation que se llevará a cabo del 28 al 29 de octubre en Lisboa, Portugal. La conferencia contará con más de cuarenta médicos de todo el mundo, mostrando las tecnologías robóticas de Stereotaxis a través de presentaciones, paneles y demostraciones.

Los temas clave incluyen:

  • Inteligencia artificial y automatización robótica en cardiología
  • Experiencia clínica con el catéter de ablación MAGiC y el sistema de mapeo EnSite X de Abbott
  • Innovaciones en catéteres robóticos para mapeo de alta densidad y ablación de campo pulsado
  • Avances en los sistemas robóticos Genesis y GenesisX
  • Técnicas de acceso alternativas desde el brazo
  • Mejores prácticas para la robótica en el tratamiento de arritmias complejas

David Fischel, Presidente y CEO de Stereotaxis, expresó su entusiasmo por la conferencia, señalando la creciente importancia de la robótica en el avance de la cardiología.

스테레오택시스 (NYSE: STXS)는 최소 침습적 혈관 내 수술 개입을 위한 외과 로봇 분야의 선두주자로, 포르투갈 리스본에서 10월 28-29일 열리는 심장 로봇 내비게이션 학회 연례 회의에 참여한다고 발표했습니다. 이 회의에는 전 세계에서 온 40명 이상의 의사가 참가하여 발표, 패널 토론 및 데모를 통해 스테레오택시스의 로봇 기술을 선보일 예정입니다.

주요 주제는 다음과 같습니다:

  • 심장학에서의 인공지능 및 로봇 자동화
  • MAGiC 절제 카테터와 Abbott의 EnSite X 맵핑 시스템에 대한 임상 경험
  • 고밀도 맵핑 및 펄스 필드 절제를 위한 로봇 카테터 혁신
  • Genesis 및 GenesisX 로봇 시스템의 발전
  • 팔에서의 대체 접근 기술
  • 복잡한 부정맥 치료를 위한 로봇의 최선의 실천 사례

스테레오택시스의 의장 겸 CEO인 David Fischel은 이번 회의에 대한 기대감을 표명하며, 로봇 기술이 심장학의 발전에 있어 점점 더 중요해지고 있음을 강조했습니다.

Stereotaxis (NYSE: STXS), un leader dans la robotique chirurgicale pour les interventions endovasculaires peu invasives, a annoncé sa participation au Congrès annuel de la Society for Cardiac Robotic Navigation qui se tiendra les 28 et 29 octobre à Lisbonne, Portugal. La conférence accueillera plus de quarante médecins du monde entier, mettant en avant les technologies robotiques de Stereotaxis à travers des présentations, des tables rondes et des démonstrations.

Les sujets clés incluent :

  • Intelligence artificielle et automatisation robotique en cardiologie
  • Expérience clinique avec le cathéter d'ablation MAGiC et le système de cartographie EnSite X d'Abbott
  • Innovations des cathéters robotiques pour la cartographie haute densité et l'ablation par champ pulsé
  • Avancées dans les systèmes robotiques Genesis et GenesisX
  • Techniques d'accès alternatives par le bras
  • Meilleures pratiques pour la robotique dans le traitement des arythmies complexes

David Fischel, Président et CEO de Stereotaxis, a exprimé son enthousiasme pour la conférence, soulignant l'importance croissante de la robotique dans l'avancement de la cardiologie.

Stereotaxis (NYSE: STXS), ein führendes Unternehmen in der chirurgischen Robotik für minimal-invasive endovaskuläre Interventionen, hat seine Teilnahme an dem Jahrestreffen der Society for Cardiac Robotic Navigation am 28.-29. Oktober in Lissabon, Portugal, angekündigt. Die Konferenz wird über vierzig Ärzte aus der ganzen Welt präsentieren, die die Robotik-Technologien von Stereotaxis in Vorträgen, Podiumsdiskussionen und Demonstrationen vorstellen.

Wichtige Themen sind:

  • Künstliche Intelligenz und robotergestützte Automatisierung in der Kardiologie
  • Klinische Erfahrungen mit dem MAGiC-Ablationskatheter und dem EnSite X-Kartierungssystem von Abbott
  • Innovationen bei robotergestützten Kathetern für hochdichte Kartierung und gepulste Feldablation
  • Fortschritte bei den robotergestützten Systemen Genesis und GenesisX
  • Alternative Zugangstechniken vom Arm
  • Best Practices für Robotik in der Behandlung komplexer Arrhythmien

David Fischel, Vorsitzender und CEO von Stereotaxis, äußerte seine Begeisterung über die Konferenz und hob die wachsende Bedeutung der Robotik in der kardiologischen Forschung hervor.

Positive
  • Participation in a major industry conference showcasing Stereotaxis' technologies
  • Exposure to key opinion leaders and potential customers from North America, Europe, and Asia
  • Opportunity to demonstrate latest innovations and clinical applications of robotic technologies
Negative
  • None.

ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation’s Annual Meeting taking place October 28-29 in Lisbon, Portugal.

The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology.

The SCRN conference includes a faculty of over forty physicians, including pioneering key opinion leaders in the field, from across North America, Europe, and Asia. Stereotaxis’ robotic technologies will be highlighted in presentations, panels, and demonstrations throughout the conference. Topics range from the use and value of robotics across a range of clinical applications, new technology developments, and the broader context of robotics in endovascular interventions. Highlighted topics include:

  • Developments with artificial intelligence, digitization of the operation room, and robotic automation
  • Clinical experience with the MAGiC ablation catheter and Abbott’s EnSite X mapping system
  • Additional robotic catheter innovations including high-density mapping and pulsed field ablation
  • Robotic system innovations with Genesis and GenesisX
  • Alternative access from the arm rather than the groin
  • Clinical value and best practices for robotics in treating complex arrhythmia

“We are excited to join SCRN this year and look forward to a particularly relevant and interesting agenda,” said David Fischel, Stereotaxis Chairman and CEO. “The strength and momentum of SCRN is reflective of the growing appreciation for the importance of robotics in advancing the cardiology community.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com


FAQ

When and where is the Society for Cardiac Robotic Navigation's Annual Meeting featuring Stereotaxis (STXS) technology?

The Society for Cardiac Robotic Navigation's Annual Meeting featuring Stereotaxis (STXS) technology is taking place on October 28-29, 2024, in Lisbon, Portugal.

What topics will be discussed at the SCRN conference related to Stereotaxis (STXS) robotic technologies?

Topics related to Stereotaxis (STXS) robotic technologies at the SCRN conference include artificial intelligence and robotic automation, clinical experience with the MAGiC ablation catheter, robotic catheter innovations, advancements in Genesis and GenesisX systems, alternative access techniques, and best practices for treating complex arrhythmia.

How many physicians are expected to participate in the SCRN conference featuring Stereotaxis (STXS) technology?

The SCRN conference featuring Stereotaxis (STXS) technology includes a faculty of over forty physicians, including key opinion leaders from North America, Europe, and Asia.

What is the significance of Stereotaxis (STXS) participating in the SCRN Annual Meeting?

Stereotaxis (STXS) participation in the SCRN Annual Meeting provides an opportunity to showcase its robotic technologies, connect with key opinion leaders, and demonstrate the growing importance of robotics in advancing cardiology to a global audience of healthcare professionals.

Stereotaxis, Inc.

NYSE:STXS

STXS Rankings

STXS Latest News

STXS Stock Data

172.00M
71.36M
15.64%
48.51%
3.89%
Medical Instruments & Supplies
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ST.LOUIS